CoChat

11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored

Open access

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Dihydrotestosterone (DHT) is regarded as the most potent natural androgen and is implicated in the development and progression of castration resistant prostate cancer (CRPC). Under castrate conditions, DHT is produced from the metabolism of the adrenal androgen precursors, DHEA and androstenedione. Recent studies have shown that the adrenal steroid 11β-hydroxyandrostenedione (11OHA4) serves as the precursor to the androgens 11-ketotestosterone (11KT) and 11-ketodihydrotestosterone (11KDHT). In this study we comprehensively assess the androgenic activity of 11KT and 11KDHT. This is the first study, to our knowledge, to show that 11KT and 11KDHT, like T and DHT, are potent and efficacious agonists of the human androgen receptor (AR) and induced both the expression of representative AR-regulated genes as well as cellular proliferation in the androgen dependent prostate cancer cell lines, LNCaP and VCaP. Proteomic analysis revealed that 11KDHT regulated the expression of more AR-regulated proteins than DHT in VCaP cells, while in vitro conversion assays showed that 11KT and 11KDHT are metabolized at a significantly lower rate in both LNCaP and VCaP cells when compared to T and DHT, respectively. Our findings show that 11KT and 11KDHT are bona fide androgens capable of inducing androgen-dependant gene expression and cell growth, and that these steroids have the potential to remain active longer than T and DHT due to the decreased rate at which they are metabolised. Collectively, our data demonstrates that 11KT and 11KDHT likely play a vital, but overlooked, role in the development and progression of CRPC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0159867

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Biosynthesis of 11KT and 11KDHT from the adrenal androgen precursor 11OHA4. Enzymes: 11βHSD2, 11β-hydroxysteroid dehydrogenase; 17βHSD2, 17β-hydroxysteroid dehydrogenase; SRD5A1, steroid 5α-reductase type 1; 3αHSD2, 3α-hydroxysteroid dehydrogenase. Steroids: 11OHA4, 11β-hydroxyandrostenedione; 11KA4, 11-ketoandrostenedione; 11KT, 11-ketotestosterone; 11OH-5α-dione, 11OH-5α-androstanedione; 11K-5α-dione, 11-keto-5α-androstanedione; 11KDHT, 11-ketodihydrotestosterone; 11OHAST, 11β-hydroxyandrosterone; 11KAST, 11-ketoadrenosterone; 11K-3α-adiol, 11-keto-5α-androstane-3α,17β-diol.
Fig 1 Biosynthesis of 11KT and 11KDHT from the adrenal androgen precursor 11OHA4. Enzymes: 11βHSD2, 11β-hydroxysteroid dehydrogenase; 17βHSD2, 17β-hydroxysteroid dehydrogenase; SRD5A1, steroid 5α-reductase type 1; 3αHSD2, 3α-hydroxysteroid dehydrogenase. Steroids: 11OHA4, 11β-hydroxyandrostenedione; 11KA4, 11-ketoandrostenedione; 11KT, 11-ketotestosterone; 11OH-5α-dione, 11OH-5α-androstanedione; 11K-5α-dione, 11-keto-5α-androstanedione; 11KDHT, 11-ketodihydrotestosterone; 11OHAST, 11β-hydroxyandrosterone; 11KAST, 11-ketoadrenosterone; 11K-3α-adiol, 11-keto-5α-androstane-3α,17β-diol.CC BY · PubMed Central
Fig 2 Binding of DHT, T, 11KDHT and 11KT to the human AR (A) and transactivation via an ARE (B and C). Binding affinities, agonist potencies and efficacies of DHT, 11KDHT, T and 11KT relative to the synthetic AR agonist mibolerone are summarised in (D). Whole cell binding assays (A) were conducted in COS-1 cells transiently transfected with pSVARo. Cells were incubated with 0.2 nM [3H]-Mib in the absence and presence of increasing concentrations of either unlabelled Mib, DHT, 11KDHT, T and 11KT for 16 hours. Results are plotted as % specific binding where the total specific binding of [3H]-Mib only is set to 100% and binding of unlabelled steroid is set as a % binding relative to that. Whole cell binding results are shown as means ± SEM of three independent experiments performed in triplicate. Transactivation assays (B and C) where performed in COS-1 cells transiently transfected with the pSVARo expression vector and the 4xSC ARE1.2-luc reporter. Agonist activity was measured by incubating cells in the presence of increasing concentrations of either Mib, DHT, T, 11KDHT or 11KT for 24 h. Induction is shown as % luciferase activity expressed in relative light units (rlu’s), with the maximal response of Mib (10−5 M) set to 100%. Luciferase assays are shown as means ± SEM of six independent experiments performed in quadruplicate.
Fig 2 Binding of DHT, T, 11KDHT and 11KT to the human AR (A) and transactivation via an ARE (B and C). Binding affinities, agonist potencies and efficacies of DHT, 11KDHT, T and 11KT relative to the synthetic AR agonist mibolerone are summarised in (D). Whole cell binding assays (A) were conducted in COS-1 cells transiently transfected with pSVARo. Cells were incubated with 0.2 nM [3H]-Mib in the absence and presence of increasing concentrations of either unlabelled Mib, DHT, 11KDHT, T and 11KT for 16 hours. Results are plotted as % specific binding where the total specific binding of [3H]-Mib only is set to 100% and binding of unlabelled steroid is set as a % binding relative to that. Whole cell binding results are shown as means ± SEM of three independent experiments performed in triplicate. Transactivation assays (B and C) where performed in COS-1 cells transiently transfected with the pSVARo expression vector and the 4xSC ARE1.2-luc reporter. Agonist activity was measured by incubating cells in the presence of increasing concentrations of either Mib, DHT, T, 11KDHT or 11KT for 24 h. Induction is shown as % luciferase activity expressed in relative light units (rlu’s), with the maximal response of Mib (10−5 M) set to 100%. Luciferase assays are shown as means ± SEM of six independent experiments performed in quadruplicate.CC BY · PubMed Central
Fig 3 Induction of AR-regulated gene expression in LNCaP cells by DHT, 11KDHT and 11KT. Cells were incubated with CS-FCS-supplemented media for 24 hours prior to treatment with 1 or 10 nM steroid for an additional 24 hours prior to analysis by qPCR. Gene expression was calculated relative to the geometric mean of the reference genes ALAS and PBGD. Fold change over vehicle was calculated using the method described by Pfaffl et al [48]. Results are shown as means ± SEM of three independent experiments performed in triplicate. Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].
Fig 3 Induction of AR-regulated gene expression in LNCaP cells by DHT, 11KDHT and 11KT. Cells were incubated with CS-FCS-supplemented media for 24 hours prior to treatment with 1 or 10 nM steroid for an additional 24 hours prior to analysis by qPCR. Gene expression was calculated relative to the geometric mean of the reference genes ALAS and PBGD. Fold change over vehicle was calculated using the method described by Pfaffl et al [48]. Results are shown as means ± SEM of three independent experiments performed in triplicate. Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].CC BY · PubMed Central
Fig 4 Induction of AR-regulated gene expression in VCaP cells by DHT, 11KDHT, T and 11KT. Cells were incubated with CS-FCS supplemented media for 24 hours prior to treatment with 1 or 10 nM steroid for an additional 24 hours prior to analysis by qPCR. Gene expression was calculated relative to the geometric mean of the reference genes ALAS and PBGD and are expressed as the fold change over the vehicle control. Results are shown as means ± SEM of three independent experiments performed in triplicate. Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].
Fig 4 Induction of AR-regulated gene expression in VCaP cells by DHT, 11KDHT, T and 11KT. Cells were incubated with CS-FCS supplemented media for 24 hours prior to treatment with 1 or 10 nM steroid for an additional 24 hours prior to analysis by qPCR. Gene expression was calculated relative to the geometric mean of the reference genes ALAS and PBGD and are expressed as the fold change over the vehicle control. Results are shown as means ± SEM of three independent experiments performed in triplicate. Data from individual experiments was all normalized using log transformation and mean-centering prior to analysis [49].CC BY · PubMed Central
Fig 5 Induction of cell proliferation in LNCaP and VCaP cells by DHT, 11KDHT, T and 11KT. Cells were incubated with media supplemented with CS-FCS for 24 hours prior to treatment with 0.1, 1 or 10 nM steroids. Resazurin assays were carried out on day 7 (LNCaP) or day 10 (VCaP) after treatment. Results are shown as means ± SEM of three independent experiments with eight replicates each.
Fig 5 Induction of cell proliferation in LNCaP and VCaP cells by DHT, 11KDHT, T and 11KT. Cells were incubated with media supplemented with CS-FCS for 24 hours prior to treatment with 0.1, 1 or 10 nM steroids. Resazurin assays were carried out on day 7 (LNCaP) or day 10 (VCaP) after treatment. Results are shown as means ± SEM of three independent experiments with eight replicates each.CC BY · PubMed Central
Fig 6 Metabolism of DHT, 11KDHT, T and 11KT by LNCaP and VCaP cells. Steroids were analysed by ultra-performance convergence chromatography-mass spectrometry (UPC2-MS/MS). Results are representative of two independent experiments performed in triplicate.
Fig 6 Metabolism of DHT, 11KDHT, T and 11KT by LNCaP and VCaP cells. Steroids were analysed by ultra-performance convergence chromatography-mass spectrometry (UPC2-MS/MS). Results are representative of two independent experiments performed in triplicate.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 151

Metadata

Authors
Pretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., & Storbeck, K.-H.
Affiliations
Stellenbosch University (ZA)
Corresponding author
  • Pretorius, Elzette
  • Africander, Donita J.
  • Vlok, Maré
  • Perkins, Meghan S.
  • Quanson, Jonathan
  • Storbeck, Karl-Heinz
Venue
PLOS ONE
Published
2016-07-21
Volume
11
Issue
7
Pages
e0159867
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2501835417
Cited by
148
References
55
Citations by year
2026: 14 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 20 · 2020: 20 · 2019: 15 · 2018: 12 · 2017: 11 · 2016: 4
FWCI
12.52
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • SUNScholar (Stellenbosch University) (submittedVersion)
Funders
  • National Research Foundation of South Africa (TTK1206061092)
  • Cancer Association of South Africa
  • Universiteit Stellenbosch
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
11-ketotestosterone, castration-resistant prostate cancer, androgen receptor, 11β-hydroxyandrostenedione, androgen metabolism, androgen-dependent gene expression, prostate cancer cell proliferation, LNCaP cells, VCaP cells
MeSH terms
Androgens, Animals, Humans, Male, Protein Binding, Receptors, Androgen, Testosterone, Response Elements, Cell Line, Tumor, Cell Proliferation, Biosynthetic Pathways, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored. https://app.cochat.ai/papers/10.1371/journal.pone.0159867
The paper
Pretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., & Storbeck, K.-H. (2016). 11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored. PLOS ONE. https://doi.org/10.1371/journal.pone.0159867

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.